目的探讨无创双水平正压通气(BiPAP)联合注射用甲泼尼龙琥珀酸钠治疗重症哮喘的临床疗效。方法将57例重症哮喘患者随机分为3组:对照组(18例)予静脉滴注地塞米松10mg,每日2次;观察组(20例)予静脉滴注甲泼尼龙琥珀酸钠80mg(每8h1次);研究组(19例)予静脉滴注甲泼尼龙琥珀酸钠80mg(每8h1次)联合BiPAP通气,比较3组患者的血气指标、生理指标的变化及气管插管率、肺炎发生率。结果研究组第1 h各指标迅速改善,第24 h时各观察指标接近正常值范围,与治疗前比较差异显著(P【0.01);且明显优于观察组与对照组。研究组气管插管率、肺炎发生率最低,与其他两组比较有统计学意义(P【0.05)。结论 BiPAP通气联合注射用甲泼尼龙琥珀酸钠是救治重症哮喘有效方法,值得临床推广应用。
Objective To explore the efficacy of Noninvasive bi-level positive airway pressure(BiPAP)combined with Methylprednisolone Sodium Succinate(MPSS) in treatment of Severe asthma. Methods:57 patients of Severe asthma were randomly divided into three group: control group(18 cases) were treated with intravenous dexamethasone 10mg,2 times a day; observation group(20 cases) were treated with intravenous MPSS 80mg q8h;study group(19 cases) were treated with intravenous MPSS 80mg q8h and BiPAP. Compared with three groups with the changes of blood gas analysis 、RR、HR and the rates of tracheal intubation 、pneumonia. Results For study group,there was a significant response after 1 hour,and the parameters observed became normal after 24 hours,and significantly better than control group and observation group. There were lowestrates of tracheal intubation and pneumonia inthe study group(P<0.05). Conclusion BiPAP combined with MPSS has a significant curative effect in treatment of Severe Asthma, deserve the clinical expansion.
Chinese Journal of Practical Internal Medicine
Noninvasive bi-level positive airway pressure
Methylprednisolone Sodium Succinate